Immunotherapy with an antibody against CD1d modulates neuroinflammation in an α-synuclein transgenic model of Lewy body like disease.
Adaptive immunity
Dementia with Lewy bodies
Innate immunity
Parkinson’s disease
T cell
α-synuclein
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
received:
20
12
2023
accepted:
01
04
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
15
4
2024
Statut:
epublish
Résumé
The neuroinflammatory process in synucleinopathies of the aging population such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB) involves microglial activation as well as infiltration of the CNS by T cells and natural killer T cells (NKTs). To evaluate the potential of targeting NKT cells to modulate neuroinflammation, we treated α-syn transgenic (tg) mice (e.g.: Thy1 promoter line 61) with an antibody against CD1d, which is a glycoprotein expressed in antigen presenting cells (APCs). CD1d-presented lipid antigens activate NKT cells through the interaction with T cell receptor in NKTs, resulting in the production of cytokines. Thus, we hypothesized that blocking the APC-NKT interaction with an anti-CD1d antibody might reduce neuroinflammation and neurodegeneration in models of DLB/PD. Treatment with the anti-CD1d antibody did not have effects on CD3 (T cells), slightly decreased CD4 and increased CD8 lymphocytes in the mice. Moreover, double labeling studies showed that compared to control (IgG) treated α-syn tg mice, treatment with anti-CD1d decreased numbers of CD3/interferon γ (IFN γ)-positive cells, consistent with NKTs. Further double labeling studies showed that CD1d-positive cells co-localized with the astrocytes marker GFAP and that anti-CD1d antibody reduced this effect. While in control α-syn tg mice CD3 positive cells were near astrocytes, this was modified by the treatment with the CD1d antibody. By qPCR, levels of IFN γ, CCL4, and interleukin-6 were increased in the IgG treated α-syn tg mice. Treatment with CD1d antibody blunted this cytokine response that was associated with reduced astrocytosis and microgliosis in the CNS of the α-syn tg mice treated with CD1d antibody. Flow cytometric analysis of immune cells in α-syn tg mice revealed that CD1d-tet + T cells were also increased in the spleen of α-syn tg mice, which treatment with the CD1d antibody reduced. Reduced neuroinflammation in the anti-CD1d-treated α-syn tg mice was associated with amelioration of neurodegenerative pathology. These results suggest that reducing infiltration of NKT cells with an antibody against CD1d might be a potential therapeutical approach for DLB/PD.
Identifiants
pubmed: 38622654
doi: 10.1186/s12974-024-03087-7
pii: 10.1186/s12974-024-03087-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467–75.
pubmed: 7857654
doi: 10.1016/0896-6273(95)90302-X
Shameli A, Xiao W, Zheng Y, Shyu S, Sumodi J, Meyerson HJ, Harding CV, Maitta RW. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology. 2016;221:333–40.
pubmed: 26517968
doi: 10.1016/j.imbio.2015.10.002
Ettle B, Kuhbandner K, Jorg S, Hoffmann A, Winkler J, Linker RA. Alpha-synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses. J Neuroinflammation. 2016;13:201.
pubmed: 27565429
pmcid: 5002168
doi: 10.1186/s12974-016-0694-4
Sommer A, Fadler T, Dorfmeister E, Hoffmann AC, Xiang W, Winner B, Prots I. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J Neuroinflammation. 2016;13:174.
pubmed: 27364890
pmcid: 4929755
doi: 10.1186/s12974-016-0632-5
Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920:16–27.
pubmed: 11193145
doi: 10.1111/j.1749-6632.2000.tb06900.x
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.
pubmed: 28592453
pmcid: 5496518
doi: 10.1212/WNL.0000000000004058
Alafuzoff I, Hartikainen P. Alpha-synucleinopathies. Handb Clin Neurol. 2017;145:339–53.
pubmed: 28987181
doi: 10.1016/B978-0-12-802395-2.00024-9
Savica R, Boeve BF, Mielke MM. When do alpha-synucleinopathies start? An Epidemiological Timeline: a review. JAMA Neurol. 2018;75:503–9.
pubmed: 29459985
doi: 10.1001/jamaneurol.2017.4243
Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657–73.
pubmed: 35246670
pmcid: 8895080
doi: 10.1038/s41577-022-00684-6
Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.
pubmed: 23463005
doi: 10.1038/ncomms2534
Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol Neurodegener. 2018;13:43.
pubmed: 30092810
pmcid: 6085656
doi: 10.1186/s13024-018-0276-2
Fiebich BL, Batista CRA, Saliba SW, Yousif NM, de Oliveira ACP. Role of Microglia TLRs in Neurodegeneration. Front Cell Neurosci. 2018;12:329.
pubmed: 30333729
pmcid: 6176466
doi: 10.3389/fncel.2018.00329
Caplan IF, Maguire-Zeiss KA. Toll-like receptor 2 signaling and current approaches for therapeutic modulation in Synucleinopathies. Front Pharmacol. 2018;9:417.
pubmed: 29780321
pmcid: 5945810
doi: 10.3389/fphar.2018.00417
Rostami J, Fotaki G, Sirois J, Mzezewa R, Bergstrom J, Essand M, Healy L, Erlandsson A. Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson’s disease brain. J Neuroinflammation. 2020;17:119.
pubmed: 32299492
pmcid: 7164247
doi: 10.1186/s12974-020-01776-7
Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, Liong C, McMurtrey C, Hildebrand WH, Mao X, et al. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature. 2017;546:656–61.
pubmed: 28636593
pmcid: 5626019
doi: 10.1038/nature22815
Iba M, Kim C, Sallin M, Kwon S, Verma A, Overk C, Rissman RA, Sen R, Sen JM, Masliah E. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and alpha-synuclein transgenic models. J Neuroinflammation. 2020;17:214.
pubmed: 32680537
pmcid: 7368752
doi: 10.1186/s12974-020-01888-0
Gate D, Tapp E, Leventhal O, Shahid M, Nonninger TJ, Yang AC, Strempfl K, Unger MS, Fehlmann T, Oh H, et al. CD4(+) T cells contribute to neurodegeneration in Lewy body dementia. Science. 2021;374:868–74.
pubmed: 34648304
pmcid: 9122025
doi: 10.1126/science.abf7266
Subleski J, Weiss JM, Wiltrout RH, Ortaldo JR. Chapter Nineteen - NK and NKT cells: The innate–adaptive interface including humoral responses. In Natural Killer Cells Edited by Lotze MT, Thomson AW: Academic Press; 2010: 255–277.
Cui Y, Wan Q. NKT cells in neurological diseases. Front Cell Neurosci. 2019;13:245.
pubmed: 31231193
pmcid: 6558384
doi: 10.3389/fncel.2019.00245
Chen Y-J, Liao H-F. NK/NKT cells and aging. Int J Gerontol. 2007;1:65–76.
doi: 10.1016/S1873-9598(08)70025-5
Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol. 2003;4:1164–5.
pubmed: 14639465
doi: 10.1038/ni1203-1164
Nair S, Dhodapkar MV. Natural killer T cells in Cancer Immunotherapy. Front Immunol. 2017;8:1178.
pubmed: 29018445
pmcid: 5614937
doi: 10.3389/fimmu.2017.01178
Holbrook J, Patel B, Camacho M, Kahanawita L, Greenland J, Williams-Gray CH. Natural killer cells have an activated profile in early Parkinson’s disease. J Neuroimmunol. 2023;382:578154.
pubmed: 37549558
doi: 10.1016/j.jneuroim.2023.578154
Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7:929–41.
pubmed: 18037897
doi: 10.1038/nri2191
Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol. 2012;12:845–57.
pubmed: 23154222
pmcid: 3740582
doi: 10.1038/nri3328
Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol. 2012;237:318–34.
pubmed: 22750327
pmcid: 3443323
doi: 10.1016/j.expneurol.2012.06.025
Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of Parkinson’s disease: the Thy1-aSyn (line 61) mice. Neurotherapeutics. 2012;9:297–314.
pubmed: 22350713
pmcid: 3337020
doi: 10.1007/s13311-012-0104-2
Rabl R, Breitschaedel C, Flunkert S, Duller S, Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H, Hutter-Paier B. Early start of progressive motor deficits in line 61 alpha-synuclein transgenic mice. BMC Neurosci. 2017;18:22.
pubmed: 28143405
pmcid: 5282838
doi: 10.1186/s12868-017-0341-8
Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68:568–78.
pubmed: 12111846
doi: 10.1002/jnr.10231
Kim C, Beilina A, Smith N, Li Y, Kim M, Kumaran R, Kaganovich A, Mamais A, Adame A, Iba M et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med 2020, 12.
Halder RC, Jahng A, Maricic I, Kumar V. Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem Res. 2007;32:257–62.
pubmed: 17006761
doi: 10.1007/s11064-006-9145-4
Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent akt activation. PLoS ONE. 2012;7:e31391.
pubmed: 22412835
pmcid: 3295805
doi: 10.1371/journal.pone.0031391
Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015;16:229–36.
pubmed: 25689443
doi: 10.1038/ni.3102
Mayne K, White JA, McMurran CE, Rivera FJ, de la Fuente AG. Aging and neurodegenerative disease: is the adaptive Immune System a friend or foe? Front Aging Neurosci. 2020;12:572090.
pubmed: 33173502
pmcid: 7538701
doi: 10.3389/fnagi.2020.572090
Molteni M, Rossetti C. Neurodegenerative diseases: the immunological perspective. J Neuroimmunol. 2017;313:109–15.
pubmed: 29153601
doi: 10.1016/j.jneuroim.2017.11.002
Labzin LI, Heneka MT, Latz E. Innate immunity and neurodegeneration. Annu Rev Med. 2018;69:437–49.
pubmed: 29106805
doi: 10.1146/annurev-med-050715-104343
Gendelman HE, Mosley RL. A perspective on roles played by Innate and adaptive immunity in the pathobiology of neurodegenerative disorders. J Neuroimmune Pharmacol. 2015;10:645–50.
pubmed: 26520433
pmcid: 4662620
doi: 10.1007/s11481-015-9639-4
Rodrigues MC, Sanberg PR, Cruz LE, Garbuzova-Davis S. The innate and adaptive immunological aspects in neurodegenerative diseases. J Neuroimmunol. 2014;269:1–8.
pubmed: 24161471
doi: 10.1016/j.jneuroim.2013.09.020
Dressman D, Elyaman W. T cells: a growing Universe of roles in neurodegenerative diseases. Neuroscientist. 2022;28:335–48.
pubmed: 34160330
doi: 10.1177/10738584211024907
Allen Reish HE, Standaert DG. Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis. 2015;5:1–19.
pubmed: 25588354
pmcid: 4405142
doi: 10.3233/JPD-140491
Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson’s disease. J Parkinsons Dis. 2013;3:493–514.
pubmed: 24275605
pmcid: 4102262
doi: 10.3233/JPD-130250
Chen Z, Chen S, Liu J. The role of T cells in the pathogenesis of Parkinson’s disease. Prog Neurobiol. 2018;169:1–23.
pubmed: 30114440
doi: 10.1016/j.pneurobio.2018.08.002
Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson’s disease. Brain. 2021;144:2047–59.
pubmed: 33704423
pmcid: 8370411
doi: 10.1093/brain/awab103
Faunce DE, Gamelli RL, Choudhry MA, Kovacs EJ. A role for CD1d-restricted NKT cells in injury-associated T cell suppression. J Leukoc Biol. 2003;73:747–55.
pubmed: 12773507
doi: 10.1189/jlb.1102540
Schneider DF, Palmer JL, Tulley JM, Kovacs EJ, Gamelli RL, Faunce DE. Prevention of NKT cell activation accelerates cutaneous wound closure and alters local inflammatory signals. J Surg Res. 2011;171:361–73.
pubmed: 21067780
doi: 10.1016/j.jss.2010.03.030
Lameris R, de Bruin RC, van Bergen En Henegouwen PM, Verheul HM, Zweegman S, de Gruijl TD, van der Vliet HJ. Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features. Immunology. 2016;149:111–21.
pubmed: 27312006
pmcid: 4981610
doi: 10.1111/imm.12635
Nambiar J, Clarke AW, Shim D, Mabon D, Tian C, Windloch K, Buhmann C, Corazon B, Lindgren M, Pollard M, et al. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model. MAbs. 2015;7:638–50.
pubmed: 25751125
pmcid: 4623119
doi: 10.1080/19420862.2015.1016693
Rayapudi M, Rajavelu P, Zhu X, Kaul A, Niranjan R, Dynda S, Mishra A, Mattner J, Zaidi A, Dutt P, Mishra A. Invariant natural killer T-cell neutralization is a possible novel therapy for human eosinophilic esophagitis. Clin Transl Immunol. 2014;3:e9.
doi: 10.1038/cti.2013.13
Chen X, Wang X, Keaton JM, Reddington F, Illarionov PA, Besra GS, Gumperz JE. Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J Immunol. 2007;178:6181–90.
pubmed: 17475845
doi: 10.4049/jimmunol.178.10.6181
Zhang Y, Fung ITH, Sankar P, Chen X, Robison LS, Ye L, D’Souza SS, Salinero AE, Kuentzel ML, Chittur SV, et al. Depletion of NK cells improves cognitive function in the Alzheimer Disease Mouse Model. J Immunol. 2020;205:502–10.
pubmed: 32503894
doi: 10.4049/jimmunol.2000037
Kumar V, Delovitch TL. Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology. 2014;142:321–36.
pubmed: 24428389
pmcid: 4080948
doi: 10.1111/imm.12247
Liu X, Li L, Si F, Huang L, Zhao Y, Zhang C, Hoft DF, Peng G. NK and NKT cells have distinct properties and functions in cancer. Oncogene. 2021;40:4521–37.
pubmed: 34120141
doi: 10.1038/s41388-021-01880-9
Krijgsman D, Hokland M, Kuppen PJK. The role of natural killer T cells in Cancer-A Phenotypical and Functional Approach. Front Immunol. 2018;9:367.
pubmed: 29535734
pmcid: 5835336
doi: 10.3389/fimmu.2018.00367
Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in Cancer Immunotherapy. Front Immunol. 2017;8:1124.
pubmed: 28955340
pmcid: 5601256
doi: 10.3389/fimmu.2017.01124
Maghazachi AA. On the role of natural killer cells in neurodegenerative diseases. Toxins (Basel). 2013;5:363–75.
pubmed: 23430541
doi: 10.3390/toxins5020363
Jadidi-Niaragh F, Shegarfi H, Naddafi F, Mirshafiey A. The role of natural killer cells in Alzheimer’s disease. Scand J Immunol. 2012;76:451–6.
pubmed: 22889057
doi: 10.1111/j.1365-3083.2012.02769.x
Solerte SB, Fioravanti M, Pascale A, Ferrari E, Govoni S, Battaini F. Increased natural killer cell cytotoxicity in Alzheimer’s disease may involve protein kinase C dysregulation. Neurobiol Aging. 1998;19:191–9.
pubmed: 9661993
doi: 10.1016/S0197-4580(98)00050-5
Earls RH, Menees KB, Chung J, Gutekunst CA, Lee HJ, Hazim MG, Rada B, Wood LB, Lee JK. NK cells clear alpha-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of alpha-synucleinopathy. Proc Natl Acad Sci U S A. 2020;117:1762–71.
pubmed: 31900358
pmcid: 6983411
doi: 10.1073/pnas.1909110117
Zhang L, Zhang Y, Fan D. Pathological role of natural killer cells in Parkinson’s Disease: a systematic review. Front Aging Neurosci. 2022;14:890816.
pubmed: 35663564
pmcid: 9157643
doi: 10.3389/fnagi.2022.890816
Snyder-Cappione JE, Tincati C, Eccles-James IG, Cappione AJ, Ndhlovu LC, Koth LL, Nixon DF. A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-alpha and MIP1-beta, a lack of IL-17, and a Th1-bias in males. PLoS ONE. 2010;5:e15412.
pubmed: 21082024
pmcid: 2972714
doi: 10.1371/journal.pone.0015412
Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313–26.
pubmed: 19441883
pmcid: 2755091
doi: 10.1089/jir.2008.0027
Chang TT, Chen JW. Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes? Cardiovasc Diabetol. 2016;15:117.
pubmed: 27553774
pmcid: 4995753
doi: 10.1186/s12933-016-0439-9
Takahashi T, Kim MS, Iwai-Shimada M, Fujimura M, Toyama T, Naganuma A, Hwang GW. Chemokine CCL4 Induced in Mouse Brain has a protective role against Methylmercury Toxicity. Toxics 2018, 6.
Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem Pharmacol. 2014;88:508–16.
pubmed: 24462903
pmcid: 3973539
doi: 10.1016/j.bcp.2014.01.015
Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis. 2018;109:249–57.
pubmed: 28400134
doi: 10.1016/j.nbd.2017.04.004
Spillantini MG, Goedert M. Neurodegeneration and the ordered assembly of alpha-synuclein. Cell Tissue Res. 2018;373:137–48.
pubmed: 29119326
doi: 10.1007/s00441-017-2706-9
Villar-Pique A, Lopes da Fonseca T, Outeiro TF. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. J Neurochem. 2016;139(Suppl 1):240–55.
pubmed: 26190401
doi: 10.1111/jnc.13249
Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 + T cells. Science. 1995;270:1811–5.
pubmed: 8525373
doi: 10.1126/science.270.5243.1811
Nuovo GJ, Alfieri ML. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Mol Med. 1996;2:358–66.
pubmed: 8784788
pmcid: 2230156
doi: 10.1007/BF03401633